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Abstract 
Aims: Diabetic neuropathy (DN) is a ‘Cinderella’ complication, particularly in the Middle East. 
A high prevalence of undiagnosed DN and those at risk of diabetic foot ulceration (DFU) is a 
major concern. We have determined the prevalence of DN and its risk factors, DFU and those at 
risk of (DFU) in patients with T2DM in secondary care in Qatar. 
Materials and methods: Adults with T2DM were randomly selected from the two National 
Diabetes Centers in Qatar. DN was defined by the presence of neuropathic symptoms and a 
vibration perception threshold (VPT)≥15V. Participants with a VPT≥25V were categorized as high 
risk for DFU. Painful DN was defined by a DN4 score ≥4. Logistic regression analysis was used 
to identify predictors of DN. 
Results: In 1,082 adults with T2DM (age 54 ±11 years, duration of diabetes 10.0 ±7.7 years, 60.6% 
males) the prevalence of DN was 23.0% (95% CI: 20.5%-25.5%), of whom 33.7% (95% CI: 
27.9%-39.6%) were at high risk of DFU and 6.3% had DFU. 82.0% of the patients with DN were 
previously undiagnosed. The prevalence of DN increased with age and duration of diabetes and 
was associated with poor glycemic control (HbA1c≥9%) AOR=2.1 (95%CI: 1.3-3.2), 
hyperlipidemia AOR=2.7 (95%CI: 1.5-5.0) and hypertension AOR=2.0 (95%CI: 1.2-3.4).  
Conclusions: Despite, DN affecting 23% of adults with T2DM, 82% had not been previously 
diagnosed with 1/3 at high risk for DFU. This argues for annual screening and identification of 
patients with DN. Furthermore, we identify hyperglycemia, hyperlipidemia and hypertension as 
predictors of DN. 
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Introduction 
Diabetic neuropathy (DN) imposes a significant health and economic burden to both the patient 
and health care providers 1. DN leads to painful diabetic neuropathy (PDN) in 18-65% 2, erectile 
dysfunction in 53-73% 3 and diabetic foot ulcers in 2-17% 1 of patients with Type 2 diabetes 
(T2DM). One in four patients with diabetic foot ulcer are at risk of amputation 4. The prevalence 
of diabetes in Qatar is 23%, almost 3-fold higher than the global average of 8% 5 and is associated 
with an increasing prevalence of the long term complications 6. Estimates of the prevalence of DN 
in people with T2DM vary from 17-53% in the Middle East and North Africa (MENA) region 7-9, 
27-32% in Europe 10-12, 21-45% in the US 13,14 and 17-62% in China 15,16. This high variability 
may be attributed to the heterogeneity of the populations studied and differing criteria for the 
diagnosis of DN. 
Screening annually for symptoms and signs of DN starting at diagnosis of T2DM is recommended 
by the 2017 American Diabetes Association position statement on DN 17. However, the prevalence 
of undiagnosed DN and those at risk of diabetic foot ulceration (DFU) remains alarmingly high 
18,19, despite the 5-year mortality of people with a diabetic foot ulcer being higher than many 
common cancers 20,21. Indeed in Qatar, 25% of patients attending secondary care were being seen 
for foot problems 22. 
Given the lack of disease modifying treatments for DN 23,24, the identification of risk factors for 
DN is key in optimizing treatment and delaying the development and progression of DN 17. Age 
and duration of diabetes are established risk factors for DN 8-10,12. Whilst, poor glycemic control 
is associated with DN 9,25, there are conflicting data on the benefits of improved glycemic control 
on DN 26-31. Studies also suggest that modifiable cardiovascular risk factors including hypertension 
13,32-35 and hyperlipidemia 36,37 are associated with DN and treatment with angiotensin converting 
enzyme (ACE) inhibitor 38-40 may improve neuropathy and statins 41,42 and fibrates 43 may reduce 
amputation.  
The objectives of this study were to establish the prevalence of DN and its risk factors, those at 
risk of DFU and with DFU in a large cohort of randomly selected people with T2DM attending 
the National Diabetes Centers in Qatar. 
Materials and Methods 
Subjects aged 18 - 85 years old with T2DM were enrolled from the National Diabetes Centers in 
Hamad General Hospital (HGH) and Al-Wakra Hospital. 1,161 subjects were randomly enrolled 
between June 2017 and February 2019. Exclusion criteria included type 1 diabetes, other causes 
of neuropathy including severe vitamin B12 deficiency, chronic hypothyroidism and 
chemotherapy.  
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This study was approved by the Institutional Review Board (IRB) of Weill Cornell Medicine-
Qatar (WCM-Q) and Hamad Medical Corporation (HMC) and all subjects gave informed consent 
to take part in the study. The research adhered to the tenets of the declaration of Helsinki. 
Demographic and metabolic measures 
Age, gender, duration of diabetes and body mass index (BMI) were recorded. Ethnicity was 
categorized as Qatari Arabs, other Arabs, South Asians, and other ethnic groups. The average 
systolic (SBP) and diastolic blood pressure (DBP) of two readings were obtained from the 
subject’s left arm while seated with the arm at heart level, using a standard zero mercury 
sphygmomanometer after 10-15 minutes of rest. A non-fasting blood sample of 10 ml was 
collected through venepuncture from each subject into EDTA tubes. The samples were kept at 
room temperature and transported within 2 hours to a central certified laboratory at HGH. Glycated 
haemoglobin (HbA1c), total cholesterol and triglyceride were measured by an autoanalyzer 
(Hitachi 747 autoanalyzer, Japan). Poor glycemic control was defined as HbA1c ≥9%. 
Hypertension was defined according to either an average SBP ≥140 mmHg and/or the use of anti-
hypertensive medication, as described in the WHO/ISH Guidelines 44. Hyperlipidemia was defined 
according to a total cholesterol level ≥6.2 mmol/L and/or triglyceride level of ≥2.3 mmol/L or if 
the patient was treated with a statin. Obesity was classified according to WHO criteria with a BMI 
≥30 Kg/m2 45. Current cigarette smoking was defined as having smoked at least one cigarette every 
day for ≥1 year preceding the study visit. Physical activity was defined as doing some physical 
activity including walking for ≥30 minutes/day for at least 3 times a week.  
Assessment of diabetic neuropathy and neuropathic complications 
DN was diagnosed clinically based on the presence of one or more neuropathic symptoms and 
impaired vibration perception in the feet. Neuropathic symptoms included burning pain, painful 
cold, electric shocks, tingling, pins and needles and numbness. Vibration perception was measured 
by a Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, Nottingham, UK) on 
the pulp of the large toe on both feet and the average value of three measurements was recorded 
as a vibration perception threshold (VPT) in Volts (V) ranging from 0 - 50V. A VPT ≥15V was 
defined as impaired vibration perception 46 and a VPT ≥25V as high risk for diabetic foot ulceration 
(DFU) 47. Previously diagnosed DN was self-reported. Painful diabetic neuropathy (PDN) was 
diagnosed using the Douleur Neuropathique en 4 (DN4) questionnaire as previously described 2. 
Statistical analysis 
The overall prevalence of DN and those at high risk of DFU were computed along with their 95% 
confidence intervals. Prevalence of DN across different demographic and health factors as 
categorical variables was summarized using frequency distributions. Variables were compared 
between patients with and without DN using the Chi-squared test.  
Binary logistic regression analysis was performed with age, duration of diabetes, gender, poor 
glycemic control, obesity, hyperlipidemia, hypertension, physical activity, smoking and ethnic 
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groups as independent variables, and DN as the dependent variable. The multiple logistic 
regression model included all variables with P value of ≤0.05 at the bivariate level. Adjusted odds 
ratios, their corresponding 95% confidence intervals (CI) and P value are presented. 
All analyses were performed using IBM-SPSS (version 23; SPSS Inc, Armonk NY). A two-tailed 
P value of ≤0.05 was considered significant. 
Results 
Prevalence of DN and those at risk of DFU 
1,082 subjects with T2DM (60.6% male) were recruited. We excluded 75 subjects with T1DM and 
4 subjects with T2DM <20 years old. The mean age and duration of diabetes were 54.3 ±11.4 years 
and 10.0 ±7.7 years, respectively.  
The prevalence of DN was 23.0% (n=249/1,082) (95% CI: 20.5%-25.5%) of whom 33.7% 
(n=84/249) (95% CI: 27.9%-39.6%) were at high risk of DFU (VPT≥25V) and 6.3% (n=15/237) 
had diabetic foot ulcers (Table 1). Impaired vibration perception in the feet (VPT≥15V) was 
detected in all subjects with clinical DN, but was also present in 7.2% (n=60/833) of subjects 
without DN. A high risk of DFU was detected in 2.2% (n=18/833) of subjects without DN. Foot 
ulcers were observed in more subjects with DN compared to subjects without DN (6.3% vs 2.1%, 
P=0.001) and in more subjects at high risk of DFU compared to subjects at low risk of DFU (11.1% 
vs 2.2%, P<0.0001). Painful diabetic neuropathy (DN4 score≥4) was present in 24.4% 
(n=203/833) of subjects without DN and in 78.7% (n=196/249) of subjects with DN. 82.0% 
(n=201/249) of patients with DN were previously undiagnosed, even though 62.7% of them were 
aware that they had foot numbness and 7.6% were at high risk of DFU. In those with DN, 20.5% 
(n=51/249) were unaware they had impaired vibration perception and 4.8% (n=12/249) were 
unaware they were at high risk of DFU. The mean total cholesterol (4.3±1.1 vs 4.5±1.2, P<0.01) 
and low-density lipoprotein (LDL) (2.4±0.9 vs 2.6±0.9, P=0.01) in patients with DN were 
significantly lower compared to patients without DN. Triglycerides (1.7±0.9 vs 1.8±1.3, P=0.14) 
and high-density lipoprotein (HDL) (1.1±0.4 vs 1.1±0.3, P=0.89) were comparable between 
patients with and without DN. 
Prevalence of diabetic neuropathy in relation to clinical and demographic factors (Table 2) 
The prevalence of DN was lower in those with increasing physical activity (P=0.004) and higher 
with increasing age (P<0.0001), duration of diabetes (P<0.0001), poor glycemic control 
(P<0.0001), hyperlipidemia (P<0.0001) and hypertension (P<0.0001) and was comparable 
between genders. The prevalence of DN was significantly higher in Qatari Arabs (29.5%) 
compared to South Asians (17.1%) (P=0.001).  
Diabetic neuropathy risk factors 
The results of binary logistic regression used to explore the odds of developing DN in relation to 
age, duration of diabetes, poor glycemic control, hyperlipidemia, hypertension, physical activity 
and ethnic groups are shown in Table 3. Obesity and smoking were not associated with DN 
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(P=0.2). The odds of developing DN were 2.5 times greater among subjects aged 51-60 years 
(P=0.001) and 3.1 times greater among subjects aged >60 years compared to subjects aged 20-50 
years (P<0.0001). The odds increased from 2.2 times greater with 11-20 years of diabetes 
(P=0.001) to 7.2 times greater with >20 years of diabetes (P<0.0001) compared to those with ≤10 
years of diabetes. The odds of developing DN were 2.1 times greater with poor glycemic control 
(P=0.001), 2.7 times greater with hyperlipidemia (P=0.002) and 2.0 times greater with 
hypertension (P=0.01) compared to subjects with HbA1c <9%, without hyperlipidemia and 
without hypertension. Physical activity was associated with a reduced prevalence of DN (odds 
ratio 0.6; 95% CI: 0.4 to 0.8; P=0.002), but after controlling for other significant predictors of DN, 
physical activity had no impact on DN (adjusted odds ratio 0.9; 95% CI: 0.6 to 1.4; P>0.05).  
The odds of developing DN in Qatari Arabs was 1.4 times greater compared to other Arabs 
(P=0.04) and 2.0 times greater compared to South Asians (P<0.0001). However, these associations 
with DN were lost after controlling for other significant predictors of DN. When comparing the 
prevalence of risk factors across the ethnic groups, there were more Qataris aged ≥60 years (37.5% 
vs 24.4% and 11.0%, P<0.0001) and less Qataris aged 20-50 years (30.0% vs 43.5% and 48.7%, 
P<0.0001) compared to other Arabs and South Asians, respectively. There were also more Qataris 
with 11-20 years of diabetes compared to other Arabs and South Asians (40.1% vs 23.4% and 
22.0%, P<0.0001) whilst there were less Qataris with ≤10 years of diabetes (47.5% vs 69.9% and 
72.5%, P<0.0001). The prevalence of hypertension in Qataris was higher compared to other Arabs 
(72.5% vs 56.4%, P=0.001) but comparable with South Asians (64.0%).  
Discussion 
In adults with T2DM attending secondary care in Qatar the prevalence of DN was 23%, of whom 
one-third were at high risk of DFU, and 6% had diabetic foot ulcers. However, 82% of patients 
with DN had not been previously diagnosed, even though 63% were aware they had foot 
numbness. Age, duration of diabetes, poor glycemic control, hyperlipidemia and hypertension are 
risk factors for DN in this population.  
The prevalence of DN varies in different countries and clinical settings. In a large clinic based 
study of 6487 patients in the UK, the prevalence of DN was 32.1% in patients with T2DM and 
increased with increasing age and duration of diabetes 10. It has been reported to be as high as 45% 
in the US 13 and 62%, in China 15, but their mean age of 73 and 66 years, respectively was much 
higher than our cohort aged 54 years. The higher prevalence of DN in Bahrain (37%)9 and Turkey 
(60%)25 compared to Qatar (23%) may be attributed to poorer glycemic control as the proportion 
with a HbA1c ≥9% in Bahrain (65%) and Turkey (79%) was much higher compared to our cohort 
in Qatar (29%).  
We show an alarmingly high prevalence of undiagnosed DN in 82% of patients attending 
secondary care in Qatar. Indeed, Wang et. al. 18 have also previously reported that 79% of patients 
have undiagnosed DN and Herman et al. 19 reported that 51% of patients with DN in the US had 
not been previously diagnosed. The high prevalence of undiagnosed DN in secondary care in Qatar 
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can be attributed to the lack of annual screening for DN and use of the 10-g monofilament which 
will identify only those with advanced neuropathy17. The prevalence of DFU in Qatar was 
comparable to the global prevalence of 6.3% 48. 
The early diagnosis and treatment of DN is key in preventing DFU and amputation 17. Indeed, in 
line with previous studies 9,25 we show that poor glycemic control is an independent risk factor for 
DN. The Kumamoto trial 26 reported that tight glucose control prevents progression of DN and the 
ACCORD 27 and the BARI 2D 28 trials reported a reduced incidence of DN with better glycemic 
control. However, the UKPDS 29, VA-CSDM 30 and Steno-2 trial 31 have shown a limited effect 
of intensive glucose control on DN. This study shows an association of DN with hyperlipidemia 
and hypertension, which is consistent with previous studies showing that DN is associated with 
hypertension 13,32-35, hyperlipidemia 36,37, BMI 9,11,13, cigarette smoking 9,36 and physical activity 8. 
Indeed, treatment with angiotensin converting enzyme (ACE) inhibitors 38-40 and statins 49,50 may 
slow the progression of DN. We also show a relationship between reduced physical activity and 
the prevalence of DN, which is consistent with a study showing that diet and exercise can improve 
neuropathy in subjects with impaired glucose tolerance 51. Previously, we reported that South 
Asians, have a lower prevalence of DN compared to Caucasians 52, particularly small fibre 
neuropathy 53. This study shows that South Asians have a lower prevalence of DN compared to 
Qatari Arabs but the association between ethnic groups and DN was lost after controlling for 
significant predictors of DN including, age, duration of diabetes, poor glycemic control, 
hyperlipidemia, hypertension and physical activity as these factors differed in the different 
ethnicities. 
There are several limitations of this study including the diagnosis of DN which was based on 
symptoms and assessment of VPT as reflected by the finding that 7.2% of participants without 
clinical DN had an abnormal VPT. This may reflect issues with the reliability and validity of 
establishing a vibration perception threshold value which like all psychophysical tests relies on 
standardisation and the participants concentration and ability to detect a sensation. Whilst we show 
associations between risk factors and DN, the cross-sectional design of this study limits the 
predictive validity of these risk factors.  
In conclusion, although the prevalence of DN was relatively low compared to previous studies 
from the Middle East region, alarmingly 82% were undiagnosed and one-third of patients with DN 
were at high risk of DFU, highlighting the need for screening for DN. The identification of  
hyperglycemia, hyperlipidemia and hypertension as modifiable risk factors provides potential 
treatment targets for DN.   
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Table 1. Prevalence of diabetic neuropathy, impaired vibration perception, high risk of diabetic 
foot ulcers, painful diabetic neuropathy, and prevalence of patients who are undiagnosed or 





n % 833 77.0% 249 23.0% 
Impaired vibration perception (VPT ≥15V) 60/833 7.2% 249/249 100.0% 
High risk of diabetic foot ulceration (VPT ≥25V) 18/833 2.2% 84/249 33.7% 
Diabetic foot ulcers 17/809 2.1% 15/237 6.3% 
Painful diabetic neuropathy (DN4 ≥4) 203/833 24.4% 196/249 78.7% 
Undiagnosed with diabetic neuropathy   201/249 82.0% 
Undiagnosed with diabetic neuropathy but aware of foot numbness   156/249 62.7% 
Undiagnosed with diabetic neuropathy but at high risk of foot ulceration   19/249 7.6% 
Unaware of impaired vibration perception (VPT ≥15V)   51/249 20.5% 
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Table 2. Prevalence of diabetic neuropathy in relation to clinical and demographic factors. 
 
Total Diabetic neuropathy 
P value No Yes 
n (%) 1082 100.0% 833 77.0% 249 23.0% N/A 
Gender Male 651 60.6% 496 76.2% 155 23.8% NS 
 Female 424 39.4% 333 78.5% 91 21.5%  
Age 20-50 years 440 41.4% 392 89.1% 48 10.9% <0.0001 
 51-60 years 375 35.3% 269 71.7% 106 28.3%  
 >60 years 247 23.3% 156 63.2% 91 36.8%  
Duration of  ≤10 years 682 63.7% 588 86.2% 94 13.8% <0.0001 
diabetes 11-20 years 302 28.2% 201 66.6% 101 33.4%  
 >20 years 86 8.0% 37 43.0% 49 57.0%  
Poor glycemic  No 695 70.8% 562 80.9% 133 19.1% <0.0001 
control Yes 287 29.2% 197 68.6% 90 31.4%  
Obesity No 442 46.6% 350 79.2% 92 20.8% NS 
 Yes 507 53.4% 383 75.5% 124 24.5%  
Hyperlipidemia No 236 24.7% 209 88.6% 27 11.4% <0.0001 
 Yes 721 75.3% 526 73.0% 195 27.0%  
Hypertension No 366 35.5% 318 86.9% 48 13.1% <0.0001 
 Yes 664 64.4% 472 71.0% 193 29.0%  
Physical activity Yes 321 38.1% 268 83.5% 53 16.5% 0.004 
 No 522 61.9% 389 74.5% 133 25.5%  
Smoking No 742 82.6% 572 77.1% 170 22.9% NS 
 Yes 156 17.4% 128 82.1% 28 17.9%  
Ethnic groups Qatari Arabs 322 30.0% 227 70.5% 95 29.5% 0.001 
 Other Arabs 300 28.0% 233 77.7% 67 22.3%  
 South Asians 397 37.0% 329 82.9% 68 17.1%  
 Others 54 5.0% 38 70.4% 16 29.6%  
 
Variables were summarized in frequency distribution and compared using x2. 
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Table 3. Predictors for diabetic neuropathy using multiple logistic regression analysis. 
 
Independent variables AOR 95% CI P value 
Age 20-50 years 1    
 51-60 years 2.5 1.4 – 4.3 0.001 
 >60 years 3.1 1.7 – 5.7 <0.0001 
Duration of diabetes ≤10 years 1    
 11-20 years 2.2 1.4 – 3.4 0.001 
 >20 years 7.2 3.8 – 13.9 <0.0001 
Poor glycemic control 2.1 1.3 - 3.2 0.001 
Hyperlipidemia  2.7 1.5 - 5.0 0.002 
Hypertension  2.0 1.2 - 3.4 0.01 
Physical activity  0.9 0.6 - 1.4 NS 
Ethnic groups Qatari Arabs 1    
 Other Arabs 1.0 0.6 - 1.6 NS 
 South Asians 0.7 0.4 - 1.1 NS 
 Others 1.4 0.5 – 3.9 NS 
 
Outcome variable: diabetic neuropathy. Independent variables: Age, duration of diabetes, poor 
glycemic control, hyperlipidemia, hypertension, physical activity and ethnic groups were 
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